Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Ocular changes in TgF344-AD rat model of Alzheimer's disease.

Tsai Y, Lu B, Ljubimov AV, Girman S, Ross-Cisneros FN, Sadun AA, Svendsen CN, Cohen RM, Wang S.

Invest Ophthalmol Vis Sci. 2014 Jan 29;55(1):523-34. doi: 10.1167/iovs.13-12888. Erratum in: Invest Ophthalmol Vis Sci. 2014;55(7):4394. Invest Ophthalmol Vis Sci. 2014 Feb;55(2):962.

2.

Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease.

Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S.

Invest Ophthalmol Vis Sci. 2009 Feb;50(2):793-800. doi: 10.1167/iovs.08-2384.

3.

Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model.

Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL.

Neuroimage. 2011 Jan;54 Suppl 1:S204-17. doi: 10.1016/j.neuroimage.2010.06.020.

4.

Amyloid precursor protein processing and retinal pathology in mouse models of Alzheimer's disease.

Dutescu RM, Li QX, Crowston J, Masters CL, Baird PN, Culvenor JG.

Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1213-21. doi: 10.1007/s00417-009-1060-3.

PMID:
19271231
5.

A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment.

Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC.

J Alzheimers Dis. 2010;20(1):113-26. doi: 10.3233/JAD-2010-1349.

PMID:
20164597
6.

Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice.

Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, Tan Z.

Am J Pathol. 2009 Nov;175(5):2099-110. doi: 10.2353/ajpath.2009.090159. Erratum in: Am J Pathol. 2010 Apr;176(4):2055.

7.

TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease.

Song M, Jin J, Lim JE, Kou J, Pattanayak A, Rehman JA, Kim HD, Tahara K, Lalonde R, Fukuchi K.

J Neuroinflammation. 2011 Aug 9;8:92. doi: 10.1186/1742-2094-8-92.

8.

Relationship between retinal lesions and inward choroidal bulging in Vogt-Koyanagi-Harada disease.

Hosoda Y, Uji A, Hangai M, Morooka S, Nishijima K, Yoshimura N.

Am J Ophthalmol. 2014 May;157(5):1056-63. doi: 10.1016/j.ajo.2014.01.015.

PMID:
24491415
9.

A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment.

Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K.

Neurobiol Dis. 2008 Jul;31(1):46-57. doi: 10.1016/j.nbd.2008.03.005.

PMID:
18504134
10.

Choroidal thinning as a new finding in Alzheimer's disease: evidence from enhanced depth imaging spectral domain optical coherence tomography.

Gharbiya M, Trebbastoni A, Parisi F, Manganiello S, Cruciani F, D'Antonio F, De Vico U, Imbriano L, Campanelli A, De Lena C.

J Alzheimers Dis. 2014;40(4):907-17. doi: 10.3233/JAD-132039.

PMID:
24577467
11.

MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice.

Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, Lemere CA.

J Neurosci. 2013 Apr 17;33(16):7027-37. doi: 10.1523/JNEUROSCI.5924-12.2013.

12.

Neurodegeneration of the retina in mouse models of Alzheimer's disease: what can we learn from the retina?

Chiu K, Chan TF, Wu A, Leung IY, So KF, Chang RC.

Age (Dordr). 2012 Jun;34(3):633-49. doi: 10.1007/s11357-011-9260-2. Review.

13.

Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease.

Knezovic A, Osmanovic-Barilar J, Curlin M, Hof PR, Simic G, Riederer P, Salkovic-Petrisic M.

J Neural Transm (Vienna). 2015 Apr;122(4):577-92. doi: 10.1007/s00702-015-1394-4.

PMID:
25808906
14.

Evaluation of the chorioretinal thickness changes in Alzheimer's disease using spectral-domain optical coherence tomography.

Bayhan HA, Aslan Bayhan S, Celikbilek A, Tanık N, Gürdal C.

Clin Exp Ophthalmol. 2015 Mar;43(2):145-51. doi: 10.1111/ceo.12386.

PMID:
24995484
15.

S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.

Zhang W, Zhang W, Li Z, Hao J, Zhang Z, Liu L, Mao N, Miao J, Zhang L.

Pharmacol Biochem Behav. 2012 Jan;100(3):361-9. doi: 10.1016/j.pbb.2011.09.012.

PMID:
21993310
16.

Alzheimer's disease in the retina: imaging retinal aβ plaques for early diagnosis and therapy assessment.

Koronyo Y, Salumbides BC, Black KL, Koronyo-Hamaoui M.

Neurodegener Dis. 2012;10(1-4):285-93. doi: 10.1159/000335154. Review.

PMID:
22343730
17.

Protection of visual functions by human neural progenitors in a rat model of retinal disease.

Gamm DM, Wang S, Lu B, Girman S, Holmes T, Bischoff N, Shearer RL, Sauvé Y, Capowski E, Svendsen CN, Lund RD.

PLoS One. 2007 Mar 28;2(3):e338.

18.

[Pathophysiology of macular diseases--morphology and function].

Iida T.

Nippon Ganka Gakkai Zasshi. 2011 Mar;115(3):238-74; discussion 275. Review. Japanese.

PMID:
21476310
19.

Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer's disease.

Xiong H, Callaghan D, Wodzinska J, Xu J, Premyslova M, Liu QY, Connelly J, Zhang W.

Neurosci Bull. 2011 Aug;27(4):221-32. doi: 10.1007/s12264-011-1015-7.

PMID:
21788993
20.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072.

PMID:
21513747
Items per page

Supplemental Content

Support Center